In tablet manufacture, aqueous dispersions of the glucomannan-rich Bletilla striata API (BSP) exhibit pseudoplastic flow at concentrations above 1.0% w/v. This property is exploited only after the raw material is normalized by sieve fractionation. Commercial veterinary-grade lots typically require delumping through an 850 µm conical sieve before blending. The API is pre-blended with microcrystalline cellulose and croscarmellose sodium in a bin blender operated at 15 rpm for 20 min; this step is not intended for API content uniformity but to reduce electrostatic charge and improve flow. Final blend lubrication with magnesium stearate 0.5% w/w is limited to 3–5 min because extended shear generates fines and elevates ejection force at the press.

If the tablet contains more than 40% w/w BSP, direct compression is generally not feasible due to poor flow and high hygroscopicity. A wet granulation route is preferred. The binder solution is prepared by dispersing BSP at 5.0% w/v in purified water heated to 40°C and passed through a 250 µm screen. The high-shear mixer is run with an impeller speed of 200–400 rpm and a chopper speed of 1,500–2,500 rpm; granulation endpoint is controlled by power draw rather than fixed time. The wet mass is discharged when the mixer torque reaches the target value established for the specific batch size. Drying is performed in a fluid-bed dryer with inlet air 60–70°C, product temperature 40–50°C, and final moisture 2.0–3.5% w/w by USP <921> Method III. The dried granules are milled through an oscillating granulator fitted with a 1.0 mm screen at 50–80 rpm.

Tablets compressed on a 10-station rotary press at 8–15 kN with 10.0 mm round tooling develop hardness 6–10 kp and friability ≤1.0% w/w by USP <1216>. Disintegration by USP <701> is typically ≤15 min in 900 mL purified water at 37°C. Dissolution testing by USP <711> in 0.1 M HCl at 50 rpm paddle must be defined by the approved veterinary marketing authorization because there is no compendial monograph for Bletilla striata veterinary tablets. Aqueous film coating with an HPMC-based system is applied to 3.0% w/w weight gain at a pan speed of 6–10 rpm, inlet air 65°C, and bed temperature 42°C. The primary process failure on production lines is sticking to upper punches at relative humidity above 55% RH; preconditioning of the blend at 35% RH for 24 h before compression reduces the incidence of picking without altering tablet hardness.

What Limits the Use of Unmodified High-Molecular-Weight BSP in Injectable Solutions?

When injectable administration is required, two simultaneous constraints apply: acceptable syringeability and sterilizing-grade filterability. Unmodified BSP fractions above approximately 100 kDa form entangled networks in aqueous solution at concentrations as low as 0.5% w/v. These solutions exhibit shear-thinning but retain viscosities that exceed typical aseptic filtration limits. Size-exclusion chromatography with multi-angle laser light scattering should be used to determine weight-average molecular weight and polydispersity; a SEC-MALLS profile using pullulan standards is appropriate for this polysaccharide. When the number-average molecular weight exceeds the range specified in the API supplier’s DMF, the filter capacity through a 0.22 µm hydrophilic PVDF membrane declines sharply after 20–40 L/m² at 0.8 bar differential pressure. The decline is caused by gel-layer formation rather than simple pore plugging; a 0.45 µm polypropylene depth prefilter removes aggregates but does not decrease the viscosity of the bulk solution.

Injectable formulation development therefore requires either controlled depolymerization or selection of a low-viscosity grade. If the API is depolymerized, comparability must be demonstrated under VICH GL1 and GL2 using glycosidic bond integrity as an analytical target. For a 1.0% w/v BSP solution in 0.9% w/v sodium chloride adjusted to pH 6.5–7.0 with 10 mM phosphate buffer, terminal moist-heat sterilization at 121°C for 15 min may reduce apparent viscosity by hydrolysis. Published degradation data for this specific veterinary-grade configuration are limited; forced degradation studies in the manufacturer’s container closure system are required. Sterile filtration through a 0.22 µm PVDF cartridge at a flux rate of 200 L/m²/h is preferred when thermal degradation is unacceptable. The filtered solution is filled into Type I borosilicate glass vials under nitrogen overlay to reduce oxidative chain scission.

The relevant release tests are USP <71> sterility, USP <85> bacterial endotoxins with an acceptance criterion appropriate for the intended route—commonly <0.25 EU/mL for intravenous products and <0.5 EU/mL for intramuscular or intra-articular products—and USP <788> particulate matter, which specifies ≤6,000 particles ≥10 µm and ≤600 particles ≥25 µm per container for small-volume injections. The selection of rubber closure must account for sorption of benzaldehyde or other residual compounds; chlorobutyl stoppers with FluroTec coating reduce leachables when the product is stored at 2–8°C for 24 months. Multi-dose presentations require antimicrobial effectiveness testing by USP <51>, but preservatives such as benzyl alcohol 0.9% w/v may increase turbidity and should be screened for incompatibility with the polysaccharide before stability commitment.

Because direct compression of the high-dose veterinary tablet formulation is generally not feasible for BSP lots with Carr Index above 30 and Hausner ratio above 1.40, dry granulation is selected when aqueous binder addition must be avoided. A roller compactor with 200 mm diameter rolls and 50 mm roll width is operated at roll pressure 4–7 MPa, roll speed 10–15 rpm, and gap 2.0–2.5 mm. The compacted ribbon density is measured and adjusted to 1.0–1.2 g/cm³ by gap and pressure changes. The ribbon is milled through a 1.0 mm screen in an oscillating mill at 50–80 rpm. Granules are collected between 125 µm and 500 µm; fines below 125 µm are recycled into the compactor feed but cannot exceed 30% w/w of the input blend because excessive recycle reduces bulk density and increases segregation.

After dry granulation, a bin blender is used to blend the granules with extra-granular sodium starch glycolate 2.0% w/w and magnesium stearate 0.75% w/w for 3–5 min at 10 rpm. The resulting granules should exhibit a Hausner ratio ≤1.25 and a flow rate ≥10 g/s through a 10 mm funnel according to the method described in USP <1174>. Capsule filling on a dosator machine requires fill weight validation because the dosator pin compresses the granule plug; tamping stations are set to 2–4 stations and tamping force 50–100 N. Hard gelatin or HPMC capsules of size 0 or size 1 are filled at room temperature 20–25°C and relative humidity <40% RH to avoid shell embrittlement.

The main process conflict in dry granulation is loss of rehydratability of the glucomannan network. Tablets made by roller compaction may show slower disintegration and lower dissolution release than wet-granulated counterparts because the compacted polysaccharide forms a gel barrier upon contact with aqueous media. The dissolution profile in 900 mL of 0.1 M HCl at 50 rpm paddle should be compared against the wet-granulated reference batch. If the release rate falls below the acceptance range, a reduction in roll pressure from 7 MPa to 4 MPa and an increase in extra-granular disintegrant to 3.0% w/w are the first process adjustments. Published data for this specific BSP roller-compacted configuration are limited; development batches must be qualified on the target production compactor rather than a laboratory benchtop unit.

When BSP is Added to Medicated Feed Before Steam Pelleting

In swine and poultry barns, feed intake is the preferred delivery route for repeated oral administration when individual animal handling is not practical. The BSP powder is added to the premix at a target concentration that must be confirmed by the phenol-sulfuric acid assay, because the polysaccharide does not contain a chromophore suitable for direct UV detection. A horizontal ribbon mixer with a working capacity of 1,000 kg and a fill volume of 60–70% is used to blend the API with ground corn or soybean meal. Mixing is performed at 25 rpm for 15 min. Homogeneity testing on 10 sampled positions using a copper sulfate tracer or the API assay must demonstrate a coefficient of variation ≤5.0% before pelleting. Dust generation is controlled by adding 2.0% w/w vegetable oil or 0.5% w/w mineral oil at the final blending stage.

The critical process conflict is steam conditioning. In a standard pellet mill, mash is conditioned at 80–85°C for 20–40 s with 16–18% w/w moisture before extrusion through a 3.0 mm die with a compression ratio of 1:10. These conditions may accelerate hydrolysis or browning of the glucomannan and reduce assayed potency. If the approved veterinary premix documentation does not support heating above 70°C, the conditioner must be operated with reduced steam and the retention time shortened to 10–15 s. An alternative is cold pelleting or extrusion at ambient temperature using a modified die, but throughput and pellet durability decline. Published data for BSP stability under commercial pelleting conditions are limited; qualification batches are required on the target production line.

Final pellet moisture is dried to ≤12% w/w and water activity <0.60 to suppress mold growth. BSP fines may carry over into subsequent batches due to electrostatic adhesion to mixer surfaces; cleaning between batches with dry compressed air and a 80 mesh screen on the dust collection system is required. In the United States, medicated feed manufacture must comply with 21 CFR 225.1 current good manufacturing practice; in the European Union, Regulation (EU) 2019/4 Annex II on medicated feed applies. Carryover limits for active substances are set in the marketing authorization and must be verified by cleaning validation using the same analytical method as the product assay.

Managing equine distal limb wounds with a topical BSP preparation requires a vehicle that maintains contact time without macerating the surrounding skin. BSP is incorporated into an oil-in-water cream because its water solubility prevents direct dissolution in an oleaginous ointment base. The cream is prepared by heating the oil phase—white petrolatum 10% w/w, cetearyl alcohol 8.0% w/w, polysorbate 60 2.0% w/w, and sorbitan stearate 1.5% w/w—to 70°C. The aqueous phase containing BSP 4.0% w/w, glycerin 5.0% w/w, and water is also heated to 70°C. The phases are combined under a high-shear homogenizer at 3,000–5,000 rpm for 15 min. Cooling to 35°C before adding the API solution avoids thermal loss of gel structure.

Hydrogel formulations are prepared by dispersing a carbomer in purified water, neutralizing with triethanolamine to pH 6.5–7.0, and then stirring in BSP 2.0–3.0% w/w. The mixing vessel must be equipped with a sweep anchor agitator at 20–40 rpm because high-shear mixing after polymer neutralization can shear-degrade the carbomer network. The final semisolid is deaerated under vacuum at -0.6 to -0.8 bar for 10 min and packed into aluminum tubes with an internal epoxy-phenolic lining. Phenoxyethanol 0.7% w/w and potassium sorbate 0.2% w/w are used as preservatives. Microbial enumeration by USP <61> and specified organisms by USP <62> are release tests. Antimicrobial effectiveness by USP <51> is performed for multi-use packages.

An incompatibility arises when BSP is combined with cationic preservatives or actives, such as chlorhexidine gluconate above 0.05% w/w, because ionic complexation can precipitate the anionic glucomannan. Benzalkonium chloride at concentrations above 0.01% w/w may produce the same effect. The pH must remain between 5.5 and 6.5; below pH 3.0, the gel structure collapses and free water separation occurs. Stability studies in the immediate container at 25°C/60% RH and 40°C/75% RH follow VICH GL3 for veterinary drug products. The release specification includes viscosity measured by a Brookfield DVII viscometer using a T-bar spindle at 10 rpm, with the acceptance range established from three pilot batches rather than a compendial value.

Drinking Water Stability and Proportioning Pump Recirculation in Swine Barns

Drinking water administration in swine barns replaces individual animal handling with proportioning pump dilution of a concentrated BSP stock solution. A stock solution is prepared at 10% w/v BSP in reverse-osmosis water, adjusted to pH 5.5–6.5 with citric acid, and preserved with potassium sorbate 0.1% w/v and sodium benzoate 0.05% w/v. The stock solution is drawn into the drinking line by a proportioning pump at a dilution ratio of 1:100 to 1:200, yielding a final concentration typically in the range 0.05–0.3% w/v. At these dilutions the solution viscosity is below 5 mPa·s and does not affect drinking nipple flow rate. However, in farms using sodium hypochlorite at 1–2 ppm free chlorine for water sanitation, the oxidant attacks glycosidic bonds; incoming water must be passed through an activated carbon bed or treated with sodium thiosulfate 0.5 ppm before the stock solution is mixed.

The recirculation loop should maintain a flow velocity of at least 0.2 m/s to prevent settling of any undissolved polysaccharide particles in dead legs. A 100 µm in-line strainer is placed before the proportioner to remove particulates that would clog the dosing pump diaphragm. The stock solution has a maximum use period of 48 h at 25°C; after this time, visible viscosity changes and microbial counts may increase. Preservative effectiveness follows USP <51> category 3 oral liquid criteria. If the product is supplied as a dry powder for reconstitution, the powder should be dissolved by sifting into water under agitation in a mixing tank at 300–500 rpm, not by direct addition to the proportioner, to avoid gel lumps.

Compliance for this route is governed by the veterinary marketing authorization and applicable national drinking water medication rules. The analytical assay for BSP in finished drinking water is the phenol-sulfuric acid method calibrated against D-glucose. Field experience indicates that biofilms in drinking lines can adsorb polysaccharides and reduce delivered dose; flushing between treatment cycles with 0.1% w/v citric acid for 12 h reduces this accumulation. If the barn water hardness exceeds 250 mg/L calcium carbonate, the stock solution may show increased turbidity due to calcium-glucomannan interactions; a chelating agent such as EDTA 0.05% w/v may be added only if approved in the marketing authorization.